化学抗原受体T细胞治疗接受者的生存率:感染,二次恶性瘤和非复发性死亡率
Tobias Tix1, Marion Subklewe2,3, Michael von Bergwelt-Baildon2,3
1Department of Medicine III - Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany, tobias.tix@med.uni-muenchen.de.
Oncology research and treatment
|November 19, 2024
概括
化学抗原受体 (CAR) T细胞疗法改善了血液癌症的结果,但幸存者面临风险. 感染是非复发性死亡率 (NRM) 的主要原因,二次癌症也令人担忧.
科学领域:
- 血液学 血液学 血液学
- 免疫治疗是一种免疫疗法.
- 在瘤学瘤学.
背景情况:
- 化学抗原受体 (CAR) T细胞疗法为复发性/耐药性血液性恶性瘤提供了治疗潜力.
- 长期幸存者面临重大挑战,包括免疫缺陷,感染,次要原发性恶性瘤 (SPMs) 和非复发性死亡率 (NRM).
研究的目的:
- 审查NRM和CAR T细胞治疗后长期并发症的发病率和危险因素.
- 为了突出管理这些生存问题的关键需求,随着CAR T细胞治疗的扩大.
主要方法:
- 文献综述侧重于NRM和CAR T细胞治疗后的长期并发症.
- 风险因素的分析,包括感染,SPM和CAR T细胞特异性毒性.
主要成果:
- 感染是NRM (>50%) 的首要驱动因素,与中性质衰竭,低血糖球蛋白血症和细胞免疫力受损有关.
- SPM是一个新兴的问题,尽管它们与CAR T细胞的直接因果关系仍在争论中.
- 特定于CAR T细胞的毒性有助于发病率,但在NRM病例中占比较小.
结论:
- 在CAR T细胞疗法后的生存受到感染,SPM和NRM的挑战.
- 预防措施,警监测和有效的毒性管理对于改善患者长期治疗结果至关重要.
更多相关视频
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.3K
06:51Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
14.9K
相关概念视频
01:40Cell-mediated Immune Responses
67.2K
Overview
67.2K
01:27Tumor Immunotherapy
480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480